Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Jak"


4 mentions found


Elanco Animal Health's decision to sell its aqua division will narrow its focus on pet health and livestock sustainability, as management prepares to launch several new products this year. ELAN 1Y mountain Elanco stock over the past year. One area it identified is pet health, a $15 billion market that has benefited from increasing pet ownership, especially among people who see their pets as family and value their animals' health care. 'Flexibility' to invest behind launches The product launches will also give Elanco a chance to prove itself. The pet health business is very competitive and, once approved, Zenrelia will compete directly with rival Zoetis' Apoquel.
Persons: Elanco, Jeff Simmons, Simmons, Credelio, Cornell University's Richard P, FactSet, Chris Schott, ELAN, Schott, Jefferies, Glen Santangelo, Eli Lilly, Jasper Hellweg, Hellweg, Zenrelia, Zoetis, — CNBC's Michael Bloom Organizations: Merck, CNBC, ELAN, Riney Canine Health, JPMorgan, Argus Locations: U.S
From Doom to Call of Duty, first-person shooters have been immensely popular for decades. But what if the thrill for video game fans was never really about the guns? Immortals of Aveum, arriving on Tuesday for Windows computers and the latest PlayStation and Xbox consoles, will test this theory. The game, set in a fantasy world with several kingdoms at war over the control of magic, abandons the tried-and-true formula of arming players with an arsenal of guns and bazookas. In the single-player game, a battlemage named Jak joins an elite militarylike force, collecting spells to make his sigils more potent.
Persons: Jak Organizations: PlayStation, Studios, Telltale Games, Electronic Arts
Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.
Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana
Au fost identificate gene asociate unor forme grave de COVID-19
  + stars: | 2020-12-12 | by ( ) www.jurnal.md   time to read: +1 min
Studiul sugerează că formele grave de COVID-19 au la bază cel puţin două mecanisme biologice: tipul apărării antivirale înnăscute - importantă în primele faze ale bolii - şi procesele inflamatorii dezvoltate de bolnav. Echipa care a realizat cercetarea consideră că testele clinice trebuie axate pe medicamentele care vizează aceste căi antivirale şi antiinflamatorii specifice. Diferenţe au fost descoperite în genele IFNAR2, TYK2, OAS1, DPP9 şi CCR2, ceea ce explică, în parte, de ce unele persoane dezvoltă forme grave de COVID-19, în timp ce altele nu sunt afectate, notează această universitate. S-a observat astfel că o diminuare a activităţii genei TYK2 protejează împotriva infectării cu SARS-CoV-2 şi că medicamente antiinflamatoare din categoria inhibitoarelor JAK produc acest efect. Acelaşi studiu mai semnalează că o creştere a activităţii genei INFAR2 creează ''probabil'' protecţie în faţa noului coronavirus, întrucât ar putea imita efectul tratamentului cu interferon.
Persons: Kenneth Baillie Organizations: Universitatea din Locations: Universitatea din Edinburgh, Diferenţe, TYK2, OAS1
Total: 4